Summary
The pharmacokinetics and haemodynamic effects of infused urapidil and an infusion-capsule combination were followed to study the correlation between the serum urapidil level and the blood pressure. Prior to urapidil administration, basal blood pressure and heart rate were measured for 16 h in 12 male hypertensive patients. Six patients received infusions lasting for 4 h of urapidil 10, 2.5 and 5 mg/h. Six patients were infused with urapidil 10 mg/h for 4 h and 2 h after the end of the infusion each took a 60-mg capsule. After a 5 day washout period the procedures were crossed over. A maximum serum urapidil level of 625±232 ng/ml was achieved at the end of the 10 mg/h infusion, when the fall in blood pressure was 37/21 mmHg. During the 2.5 and 5 mg/h infusions the serum urapidil level was 330 and 420 ng/ml, respectively, and the corresponding decreases in blood pressure were 28/16 mmHg and 31/8 mmHg. Although the urapidil concentration 1 hour after beginning the infusion was only 184±89 ng/ml a near maximal blood pressure decrease had already occurred 33±9/20±8 mmHg, whereas, 1 h after the end of the infusion the reduction in blood pressure was only 10±12/3±8 mm, with a urapidil concentration of 358±120 ng/ml. During the plateau phases of both the infusion and infusion-capsule treatments the falls in blood pressure followed the serum urapidil levels. Only in the initial rising and final falling phases of the treatments were the pharmacodynamics and pharmacokinetics of urapidil not correlated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bories P, Ampelas M, Bauret P, Michel H (1986) Pharmacokinetics of urapidil in liver impairment. J Roy Soc Med 101: 53–56
Brogden RN, Heel RC, Speight TM, Avery GS (1981) Trazodone: A review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 21: 401–429
Daniell HB, Walle T, Gaffney TE, Webb JG (1979) Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther 208: 354–359
Fisher R, Haerlin R, Steinijans VW, Zech K, Bruckschen EG (1981) Preliminary results on the correlation between serum level and antihypertensive effect of urapidil (Ebrantil). Methods Find Exp Clin Pharmacol 3 [Suppl 1]: 89S-93S
Fitzgerald JD (1980) Propranolol. In: A Scriabine (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, pp 195–208
Godehardt E, Wambach G, Heitz W, Steinijans VW, Haerlin R, Kaufmann W (1986) Pharmacokinetics of urapidil in patients with normal and impaired renal function. J Roy Soc Med 101: 71–86
Gielsdorf W, Nieder M, Molz K-H, Jager H, Haerlin R, Radtke H-W (1986) Zur Pharmakokinetik und Bioverfügbarkeit von Urapidil — In vitro/in vivo-Korrelation verschiedener experimenteller Zubereitungen. Arzneimittelforsch 36 (II), VIII: 1265–1267
Kirsten R, Nelson K, Neff J, Haerlin R, Steinijans VW, Radke HW (1986) Pharmacodynamics and pharmacokinetics of three different urapidil doses infused in hypertensive patients. Eur J Clin Pharmacol 30: 549–552
Klemm K (1982) Struktur-Wirkungs-Beziehungen N1-substituierter N4-Arylpiperazine und physikalisch-chemische Eigenschaften von Urapidil. In: Kaufmann W, Bruckschen EG (eds), Urapidil — Darstellung einer antihypertensiven Substanz. Excerpta Medica, Amsterdam pp 26–33
Leibetseder F (1982) Beziehung zwischen Blutdruck und Serumspiegel von Urapidil. In: Urapidil — Darstellung einer neuen antihypertensiven Substanz. Kaufmann W, Bruckschen EG (eds). Excerpta Medica, Amsterdam pp 71–80
Magometschnigg D, Vacher S (1986) Acute hemodynamic responses to single intravenous doses of urapidil in essential hypertensive patients. J Roy Soc Med 101: 47–51
Michel JP, Hessel L, Zech K, Steinijans VW (1986) Pharmacokinetics and pharmacodynamics of urapidil in the elderly. J Roy Soc Med 101: 39–45
Mönch E, Jäckel R, Kohlen W, Diel H (1982) Serumkonzentrationen von Urapidil bei Normo- und Hypertonikern. In: Kaufmann W, Bruckschen EG (eds), Urapidil — Darstellung einer neuen antihypertensiven Substanz. Excerpta Medica, Amsterdam, pp 65–70
Nieder M, Dilger C, Haerlin R (1985) Quantitation of urapidil and its metabolites in human serum by high performance liquid chromatography. J High Res Chromatogr Chromatogr Commun 8: 224–229
Schoetensack W, Bruckschen EG, Zech K (1983) Urapidil. In: Scriabine A (ed) New drugs annual: Cardiovascular drugs. Raven Press, New York 19–48
Wellstein A, Palm D, Pitschner HF, Belz GG (1985) Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol 29: 131–147
Werner LH, Barrett WE (1967) Adrenergic blocking agents. In: Schittler E (ed) Medical chemistry, vol 7. Antihypertensive agents. Academic Press, New York London 331–392
Wylie DW, Archer S (1962) Structure-activity relationship of 1-(indolyl)-ethyl-4-arylpiperazines. A new series of tranquilizers. J Med Pharm Chem 5: 932
Zech K, Eltze M, Kilian U, Sanders H, Kolassa N (1984) Biotransformation of urapidil: metabolites in serum and urine and their biological activity in vitro and in vivo. Arch Int Pharmacodyn Ther 272: 180–196
Zech K, Steinijans VW, Radtke HW (1986) Pharmacokinetics of urapidil in normal subjects. J Roy Soc Med 101: 29–38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirsten, R., Nelson, K., Molz, K.H. et al. Pharmacodynamics and pharmacokinetics of urapidil in hypertensive patients: A crossover study comparing infusion with an infusion-capsule combination. Eur J Clin Pharmacol 32, 61–65 (1987). https://doi.org/10.1007/BF00609958
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609958